Improving the quality and efficiency of follow-up after curative treatment for breast cancer - rationale and study design of the MaCare trial

被引:18
|
作者
Kimman, Merel L. [1 ]
Voogd, Adri C.
Dirksen, Carmen D.
Falger, Paul
Hupperets, Pierre
Keymeulen, Kristien
Hebly, Marlene
Dehing, Cary
Lambin, Philippe
Boersma, Liesbeth J.
机构
[1] Maastro Clin, Maastricht, Netherlands
[2] Maastricht Univ, Dept GROW MAASTRO, Maastricht, Netherlands
[3] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands
[4] Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[5] Univ Hosp Maastricht, Dept Med Psychol, Maastricht, Netherlands
[6] Univ Hosp Maastricht, Dept Med Oncol, Maastricht, Netherlands
[7] Univ Hosp Maastricht, Dept Surg, Maastricht, Netherlands
[8] Univ Hosp Maastricht, Dept Radiat Oncol, Maastricht, Netherlands
关键词
D O I
10.1186/1471-2407-7-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: After curative treatment for breast cancer women frequently attend scheduled follow-up examinations. Usually the follow-up is most frequent in the first 2-3 years ( 2-4 times a year); thereafter the frequency is reduced to once a year in most countries. Its main aim is to detect local disease recurrence, or a second primary breast cancer, but also to provide information and psychosocial support. However, the cost-effectiveness of these frequent visits is under much debate, leading to a search for less intensive and more cost-effective follow-up strategies. In this paper the design of the MaCare trial is described. This trial compares the cost-effectiveness of four follow-up strategies for curatively treated breast cancer patients. We investigate the costs and effects of nurse-led telephone follow-up and a short educational group programme. Methods/design: The MaCare trial is a multi centre randomised clinical trial in which 320 breast cancer patients are randomised into four follow-up strategies, focussed on the first 18 months after treatment: 1) standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the educational group programme; 4) arm 2 with the educational group programme. Data is collected at baseline and 3, 6, 12 and 18 months after treatment. The primary endpoint of the trial is cancer-specific quality of life as measured by the global health/QoL scale of the EORTC QLQ-C30. Secondary outcomes are perceived feelings of control, anxiety, patients' satisfaction with follow-up and costs. A cost-effectiveness analysis will be performed from a societal perspective. Discussion: Reduced follow-up strategies for breast cancer have not yet been widely applied in clinical practice. Improvement of psychosocial support and information to patients could lead to a better acceptance of reduced follow-up. The MaCare trial combines a reduced follow-up strategy with additional psychosocial support. Less frequent follow-up can reduce the burden on medical specialists and costs. The educational group programme can improve QoL of patients, but also less frequent follow-up can improve QoL by reducing the anxiety experienced for each follow-up visit. Results of the trial will provide knowledge on both costs and psychosocial aspects regarding follow-up and are expected in 2009.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Improving the quality and efficiency of follow-up after curative treatment for breast cancer – rationale and study design of the MaCare trial
    Merel L Kimman
    Adri C Voogd
    Carmen D Dirksen
    Paul Falger
    Pierre Hupperets
    Kristien Keymeulen
    Marlene Hebly
    Cary Dehing
    Philippe Lambin
    Liesbeth J Boersma
    BMC Cancer, 7
  • [2] IMPROVING THE QUALITY AND EFFICIENCY OF FOLLOW-UP AFTER CURATIVE TREATMENT FOR BREAST CANCER
    Kimman, M.
    Dirksen, C.
    Lambin, P.
    Boersma, L.
    RADIOTHERAPY AND ONCOLOGY, 2009, 92 : S113 - S114
  • [3] Improving the quality and efficiency of breast cancer follow up: a randomised controlled trial investigating nurse-led follow-up
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 93 - 93
  • [4] Improving the quality and efficiency of breast cancer follow-up: results from an RCT
    Kimman, M. L.
    Dirksen, C. D.
    Voogd, A. G.
    Falger, P.
    Hupperets, P.
    Kessels, A.
    Keymeulen, K.
    Gijsen, B.
    Lambin, P.
    Boersma, L. J.
    EJC SUPPLEMENTS, 2010, 8 (03): : 207 - 207
  • [5] Follow-up after curative treatment for colorectal cancer COLOFOL
    Wille-Jorgensen, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 56 - 56
  • [6] Follow-up principles after curative treatment in renal cancer
    Kazan, Ercan
    Gemalmaz, Hakan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (03): : 194 - 200
  • [7] Follow-up after treatment for breast cancer
    Murphy, KC
    Coppin, CML
    Kader, HEHA
    Norris, BD
    Weir, LM
    Hugi, MR
    Olivotto, IA
    Lees, AW
    Graydon, JE
    Bowman, DM
    Bouchard, F
    Mickelson, WP
    Levine, MN
    McGregor, M
    Olweny, C
    Ayoub, J
    Armann, D
    Baldwin, J
    Clarke, HF
    Couture, J
    Davidson, JSD
    Grant, B
    Hartrick, G
    Hicks, S
    Hiscock, J
    Kaizer, L
    Kindrat, P
    Kuusk, U
    McIntosh-Burgess, B
    Miller, AS
    Smart, M
    Theman, TW
    Woodland, H
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1998, 158 : S65 - S70
  • [8] FOLLOW-UP OF THE PATIENT AFTER CURATIVE TREATMENT
    Westeel, V.
    LUNG CANCER, 2011, 71 : S10 - S11
  • [9] A longitudinal study of follow-up activities after curative treatment for head and neck cancer
    Pagh, Anja
    Grau, Cai
    Overgaard, Jens
    ACTA ONCOLOGICA, 2015, 54 (05) : 813 - 819
  • [10] Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer: a randomised controlled trial
    Bloebaum, M. M. F.
    Kimman, M. L.
    Houben, R.
    Boersma, L. J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 319 - 319